Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids
Wei Qiu,Ming Zhou,Mausumi Mazumdar,Arezki Azzi,Dalila Ghanmi,Van Luu‐The,Fernand Labrie,Sheng‐Xiang Lin
DOI: https://doi.org/10.1074/jbc.m606784200
2007-01-01
Abstract:Human type 5 17β-hydroxysteroid dehydrogenase plays a crucial role in local androgen formation in prostate tissue. Several chemicals were synthesized and tested for their ability to inhibit this enzyme, and a series of estradiol derivatives bearing a lactone on the D-ring were found to inhibit its activity efficiently. The crystal structure of the type 5 enzyme in complex with NADP and such a novel inhibitor, EM1404, was determined to a resolution of 1.30Aå. Significantly more hydrogen bonding and hydrophobic interactions were defined between EM1404 and the enzyme than in the substrate ternary complex. The lactone ring of EM1404 accounts for important interactions with the enzyme, whereas the amide group at the opposite end of the inhibitor contributes to the stability of three protein loops involved in the construction of the substrate binding site. EM1404 has a strong competitive inhibition, with a Ki of 6.9 ± 1.4 nm, demonstrating 40 times higher affinity than that of the best inhibitor previously reported. This is observed despite the fact that the inhibitor occupies only part of the binding cavity. Attempts to soak the inhibitor into crystals of the binary complex with NADP were unsuccessful, yielding a structure with a polyethylene glycol fragment occupying the substrate binding site. The relative crystal packing is discussed. Combined studies of small molecule inhibitor synthesis, x-ray crystallography, enzyme inhibition, and molecular modeling make it possible to analyze the plasticity of the substrate binding site of the enzyme, which is essential for developing more potent and specific inhibitors for hormone-dependent cancer therapy. Human type 5 17β-hydroxysteroid dehydrogenase plays a crucial role in local androgen formation in prostate tissue. Several chemicals were synthesized and tested for their ability to inhibit this enzyme, and a series of estradiol derivatives bearing a lactone on the D-ring were found to inhibit its activity efficiently. The crystal structure of the type 5 enzyme in complex with NADP and such a novel inhibitor, EM1404, was determined to a resolution of 1.30Aå. Significantly more hydrogen bonding and hydrophobic interactions were defined between EM1404 and the enzyme than in the substrate ternary complex. The lactone ring of EM1404 accounts for important interactions with the enzyme, whereas the amide group at the opposite end of the inhibitor contributes to the stability of three protein loops involved in the construction of the substrate binding site. EM1404 has a strong competitive inhibition, with a Ki of 6.9 ± 1.4 nm, demonstrating 40 times higher affinity than that of the best inhibitor previously reported. This is observed despite the fact that the inhibitor occupies only part of the binding cavity. Attempts to soak the inhibitor into crystals of the binary complex with NADP were unsuccessful, yielding a structure with a polyethylene glycol fragment occupying the substrate binding site. The relative crystal packing is discussed. Combined studies of small molecule inhibitor synthesis, x-ray crystallography, enzyme inhibition, and molecular modeling make it possible to analyze the plasticity of the substrate binding site of the enzyme, which is essential for developing more potent and specific inhibitors for hormone-dependent cancer therapy. According to the American Cancer Society, prostate cancer is the most common malignant tumor, excluding skin cancers, in American men. It is estimated that ∼232,090 new cases of prostate cancer will be diagnosed in the US during 2005 with 30,350 deaths (www.cancer.org). The growth and function of the prostate is dependent on androgens, which play important roles in the pathogenesis of prostate cancer (1Lopez-Otin C. Diamandis E.P. Endocr. Rev. 1998; 19: 365-396Crossref PubMed Scopus (182) Google Scholar). Androgen withdrawal triggers the programmed cell apoptosis in both normal prostate glandular epithelia and androgen-dependent prostate cancer cells. Androgen-independent prostate cancer cells do not initiate the programmed cell death pathway upon androgen withdrawal; however, they do retain the cellular machinery necessary to activate the apoptotic cascade when sufficiently damaged by exogenous agents (2Denmeade S.R. Lin X.S. Isaacs J.T. Prostate. 1996; 28: 251-265Crossref PubMed Scopus (389) Google Scholar). In prostate cancer, the balance between cell proliferation and programmed cell death is lost, thus more cell proliferation results in net cell growth. An important finding in prostate cancer research is that ∼50% of dihydrotestosterone, the most potent natural androgen, remains in the prostatic tissue of patients who have undergone surgical or chemical castration (3Labrie F. Dupont A. Belanger A. Giguere M. Lacoursiere Y. Emond J. Monfette G. Bergeron V. J. Steroid Biochem. 1985; 23: 833-841Crossref PubMed Scopus (140) Google Scholar). In fact, prostatic tissue is able to efficiently transform the inactive adrenal steroid precursor dehydroepiandrosterone, into the active androgen dihydrotestosterone, in a new androgen biosynthetic pathway in which human type 5 17β-hydroxysteroid dehydrogenase (17β-HSD5) 4The abbreviations used are: 17β-HSD5, 17β-hydroxysteroid dehydrogenase type 5; AKR, aldoketo reductase; PEG, polyethylene glycol; EM1404, 3-carboxamido-1,3,5-(10)-estratrien-17(R)-spiro-2′-(5′,5′-dimethyl-6′-oxo)tetrahydropyran, C25H30O3N; E2, estradiol. 4The abbreviations used are: 17β-HSD5, 17β-hydroxysteroid dehydrogenase type 5; AKR, aldoketo reductase; PEG, polyethylene glycol; EM1404, 3-carboxamido-1,3,5-(10)-estratrien-17(R)-spiro-2′-(5′,5′-dimethyl-6′-oxo)tetrahydropyran, C25H30O3N; E2, estradiol. is involved (4Pelletier G. Luu-The V. Tetu B. Labrie F. J. Histochem. Cytochem. 1999; 47: 731-738Crossref PubMed Scopus (92) Google Scholar, 5Pelletier G. Li S. Luu-The V. Tremblay Y. Belanger A. Labrie F. J. Endocrinol. 2001; 171: 373-383Crossref PubMed Scopus (81) Google Scholar, 6El-Alfy M. Luu-The V. Huang X.F. Berger L. Labrie F. Pelletier G. Endocrinology. 1999; 140: 1481-1491Crossref PubMed Google Scholar, 7Labrie F. Cusan L. Gomez J.L. Candas B. Belanger A. Luu-The V. Labrie C. Simard J. Med. Sci. (Paris). 2003; 19: 910-919Crossref PubMed Scopus (4) Google Scholar). In practice, hormonal therapy with combined androgen blockade could lead to even longer term control of localized prostate cancer (8Labrie F. Dupont A. Belanger A. Cusan L. Lacourciere Y. Monfette G. Laberge J.G. Emond J.P. Fazekas A.T. Raynaud J.P. Husson J.M. Clin. Invest. Med. 1982; 5: 267-275PubMed Google Scholar, 9Labrie F. Candas B. Gomez J.L. Cusan L. Urology. 2002; 60: 115-119Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). 17β-HSD5 has also been known as type 2 3α-HSD (10Lin H.K. Jez J.M. Schlegel B.P. Peehl D.M. Pachter J.A. Penning T.M. Mol. Endocrinol. 1997; 11: 1971-1984Crossref PubMed Google Scholar), prostaglandin 11-ketoreductase (prostaglandin F synthetase) (11Matsuura K. Shiraishi H. Hara A. Sato K. Deyashiki Y. Ninomiya M. Sakai S. J. Biochem. (Tokyo). 1998; 124: 940-946Crossref PubMed Scopus (158) Google Scholar), and dihydrodiol dehydrogenase (12Burczynski M.E. Harvey R.G. Penning T.M. Biochemistry. 1998; 37: 6781-6790Crossref PubMed Scopus (132) Google Scholar). It is a member of the aldoketo reductase (AKR) family with a designated name of AKR1C3 (13Jez J.M. Bennett M.J. Schlegel B.P. Lewis M. Penning T.M. Biochem. J. 1997; 326: 625-636Crossref PubMed Scopus (534) Google Scholar, 14Jez J.M. Flynn T.G. Penning T.M. Biochem. Pharmacol. 1997; 54: 639-647Crossref PubMed Scopus (335) Google Scholar) and was first cloned from human prostate and placenta cDNA libraries (10Lin H.K. Jez J.M. Schlegel B.P. Peehl D.M. Pachter J.A. Penning T.M. Mol. Endocrinol. 1997; 11: 1971-1984Crossref PubMed Google Scholar, 15Dufort I. Rheault P. Huang X.F. Soucy P. Luu-The V. Endocrinology. 1999; 140: 568-574Crossref PubMed Scopus (240) Google Scholar). It has been proven that this enzyme has a relatively high 17β-HSD activity that transforms Δ4-androstene-3,17-dione (4-dione, a weak androgen) to testosterone (a potent androgen). This enzyme has been immunocytochemically localized in human prostate tissues, and it has been proposed to contribute to local androgen formation in prostate (4Pelletier G. Luu-The V. Tetu B. Labrie F. J. Histochem. Cytochem. 1999; 47: 731-738Crossref PubMed Scopus (92) Google Scholar, 5Pelletier G. Li S. Luu-The V. Tremblay Y. Belanger A. Labrie F. J. Endocrinol. 2001; 171: 373-383Crossref PubMed Scopus (81) Google Scholar, 6El-Alfy M. Luu-The V. Huang X.F. Berger L. Labrie F. Pelletier G. Endocrinology. 1999; 140: 1481-1491Crossref PubMed Google Scholar, 16Lin H.K. Steckelbroeck S. Fung K.M. Jones A.N. Penning T.M. Steroids. 2004; 69: 795-801Crossref PubMed Scopus (110) Google Scholar, 17Nakamura Y. Suzuki T. Nakabayashi M. Endoh M. Sakamoto K. Mikami Y. Moriya T. Ito A. Takahashi S. Yamada S. Arai Y. Sasano H. Endocr. Relat. Cancer. 2005; 12: 101-107Crossref PubMed Scopus (81) Google Scholar). The enzyme conformational change during 4-dione to testosterone conversion was demonstrated by the first crystal structures of 17β-HSD5 in complex with either 4-dione or testosterone (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar, 19Qiu W. Zhou M. Labrie F. Lin S-X. Mol. Endocrinol. 2004; 18: 1798-1807Crossref PubMed Scopus (65) Google Scholar). The 11-ketoreductase activity of this enzyme has also been studied in association with prostaglandin D2 and some inhibitors (20Komoto J. Yamada T. Watanabe K. Takusagawa F. Biochemistry. 2004; 43: 2188-2198Crossref PubMed Scopus (84) Google Scholar, 21Lovering A.L. Ride J.P. Bunce C.M. Desmond J.C. Cummings S.M. White S.A. Cancer Res. 2004; 64: 1802-1810Crossref PubMed Scopus (103) Google Scholar). Blockade of this enzyme could lead to the activation of a nuclear receptor (peroxisome proliferator-activated receptor-γ), which induces cell differentiation, and results in apoptosis in many cell types and cancers (22Wick M. Hurteau G. Dessev C. Chan D. Geraci M.W. Winn R.A. Heasley L.E. Nemenoff R.A. Mol. Pharmacol. 2002; 62: 1207-1214Crossref PubMed Scopus (140) Google Scholar, 23Desmond J.C. Mountford J.C. Drayson M.T. Walker E.A. Hewison M. Ride J.P. Luong Q.T. Hayden R.E. Vanin E.F. Bunce C.M. Cancer Res. 2003; 63: 505-512PubMed Google Scholar). The gene that encodes 17β-HSD5 was assigned to human chromosome bands 10p15 and p14 (24Rheault P. Dufort I. Soucy P. Luu-The V. Cytogenet. Cell Genet. 1999; 84: 241-242Crossref PubMed Google Scholar). 17β-HSD5 mRNA was also reported to be expressed in prostate cancer tissues (25Koh E. Noda T. Kanaya J. Namiki M. Prostate. 2002; 53: 154-159Crossref PubMed Scopus (82) Google Scholar). In a recent study, 17β-HSD5 immunoreactivity was detected in 77% of carcinoma cells from prostate cancer tissues and was positively associated with the clinical stage of the disease (17Nakamura Y. Suzuki T. Nakabayashi M. Endoh M. Sakamoto K. Mikami Y. Moriya T. Ito A. Takahashi S. Yamada S. Arai Y. Sasano H. Endocr. Relat. Cancer. 2005; 12: 101-107Crossref PubMed Scopus (81) Google Scholar). This provides some evidence that 17β-HSD5 may possibly be involved in the increase of the local concentration of testosterone. Both reductive and oxidative 17β-HSD activities are present in prostate tissue (26Bartsch W. Greeve J. Voigt K.D. J. Steroid. Biochem. 1987; 28: 35-42Crossref PubMed Scopus (17) Google Scholar, 27Martel C. Rheaume E. Takahashi M. Trudel C. Couet J. Luu-The V. Simard J. Labrie F. J. Steroid Biochem. Mol. Biol. 1992; 41: 597-603Crossref PubMed Scopus (234) Google Scholar), assumed by different members of the 17β-HSD family members. Using the androgen-sensitive LNCaP prostate cancer cell line as a cell model to study the progression of prostate cancer, it has been reported that substantial changes in androgen and estrogen metabolism occur in the cells during this process. A remarkable decrease in the oxidative 17β-hydroxysteroid dehydrogenase activity was seen, whereas the reductive activity (including 17β-HSD5 and 17β-HSD7) seemed to increase (28Soronen P. Laiti M. Torn S. Harkonen P. Patrikainen L. Li Y. Pulkka A. Kurkela R. Herrala A. Kaija H. Isomaa V. Vihko P. J. Steroid Biochem. Mol. Biol. 2004; 92: 281-286Crossref PubMed Scopus (70) Google Scholar). It has also been reported that 17β-HSD5 mRNA expression was significantly higher in breast tumor specimens than in normal tissue after analysis of 794 breast carcinoma specimens by tissue microarray and normal histologic sections (29Oduwole O.O. Li Y. Isomaa V.V. Mantyniemi A. Pulkka A.E. Soini Y. Vihko P.T. Cancer Res. 2004; 64: 7604-7609Crossref PubMed Scopus (107) Google Scholar). This suggests that the ability of 17β-HSD5 to regulate estrogen metabolism may play an important role in breast cancer development. It is also interesting to point out that 17β-HSD5 plays an important site-specific role in androgen generation in adipose tissue in women with simple obesity (30Quinkler M. Sinha B. Tomlinson J.W. Bujalska I.J. Stewart P.M. Arlt W. J. Endocrinol. 2004; 183: 331-342Crossref PubMed Scopus (132) Google Scholar). Due to the importance of this enzyme, not only in prostate cancer research but also in other hormone-related diseases, the design of an inhibitor targeting this key enzyme has been widely pursued (31Krazeisen A. Breitling R. Moller G. Adamski J. Adv. Exp. Med. Biol. 2002; 505: 151-161Crossref PubMed Scopus (26) Google Scholar, 32Penning T.M. Burczynski M.E. Jez J.M. Lin H.K. Ma H. Moore M. Ratnam K. Palackal N. Mol. Cell. Endocrinol. 2001; 171: 137-149Crossref PubMed Scopus (87) Google Scholar, 33Bauman D.R. Rudnick S.I. Szewczuk L.M. Jin Y. Gopishetty S. Penning T.M. Mol. Pharmacol. 2005; 67: 60-68Crossref PubMed Scopus (109) Google Scholar, 34Labrie F. Belanger A. Gauthier S. Luu-The V. Merand Y. Poirier D. Provencher L. Singh S.M. Inhibitors of Type 5 and Type 3 17beta-Hydroxysteroid Dehydrogenase and Methods for Their Use. 1999; (Canada PCT, WO99/46279)Google Scholar, 35Krazeisen A. Breitling R. Moller G. Adamski J. Mol. Cell. Endocrinol. 2001; 171: 151-162Crossref PubMed Scopus (142) Google Scholar). The crystal structure of 17β-HSD5 is a necessary prerequisite for structure-based drug design. The enzyme was first crystallized in our laboratory (36Zhou M. Qiu W. Chang H.J. Gangloff A. Lin S.X. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002; 58: 1048-1050Crossref PubMed Scopus (7) Google Scholar), and structures in complex with testosterone or 4-dione were determined (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar, 19Qiu W. Zhou M. Labrie F. Lin S-X. Mol. Endocrinol. 2004; 18: 1798-1807Crossref PubMed Scopus (65) Google Scholar). To date, eight crystal structures of AKR1C3 in different complexes have been published (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar, 20Komoto J. Yamada T. Watanabe K. Takusagawa F. Biochemistry. 2004; 43: 2188-2198Crossref PubMed Scopus (84) Google Scholar, 21Lovering A.L. Ride J.P. Bunce C.M. Desmond J.C. Cummings S.M. White S.A. Cancer Res. 2004; 64: 1802-1810Crossref PubMed Scopus (103) Google Scholar). The plasticity of its substrate binding site in accommodating different ligands and its importance in hormone-related diseases led us to investigate further the structure-function relationships of this enzyme. The functional plasticity of the AKR1C3 as well as 1C1 and 1C2 enzymes has been discussed by Penning and colleagues previously (37Penning T.M. Burczynski M.E. Jez J.M. Hung C.F. Lin H.K. Ma H. Moore M. Palackal N. Ratnam K. Biochem. J. 2000; 351: 67-77Crossref PubMed Scopus (540) Google Scholar). Being aware that any subtle difference at the active site could be important for structure-based inhibitor design, we have studied the active site of the enzyme in detail by comparing the different docking properties of various inhibitors and ligands in the crystallographic structures. In this study, we report the crystal structure of 17β-HSD5 in complex with a potent inhibitor EM1404 and another structure with a segment of polyethylene glycol (PEG) made from 6 ethylene glycol units (C12H25O6) bound in the active site. Enzyme inhibition by EM1404 was also studied, and the comparison with other inhibitors has been discussed. Furthermore, we intended to explore the interactions between this potent inhibitor and its target enzyme, 17β-HSD5, and to provide suggestions for the improvement of inhibitor design based on the crystal structure. Purification and Crystallization—Human 17β-HSD5-glutathione S-transferase was overexpressed in Escherichia coli and purified by glutathione S-transferase affinity column and a Blue Sepharose column as described previously (36Zhou M. Qiu W. Chang H.J. Gangloff A. Lin S.X. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002; 58: 1048-1050Crossref PubMed Scopus (7) Google Scholar). After purification the protein was kept in potassium phosphate stock buffer of pH 7.5, in the presence of 10 mm K2HPO4, 1 mm EDTA, 1 mm dithiothreitol, 0.05% decylmaltoside, 1.2 mm NADP. The glutathione S-transferase tag was cleaved by overnight incubation at 4 °C with Thrombin protease. EM1404 was co-crystallized with 17β-HSD5 and NADP. Due to the low solubility of EM1404, it was first dissolved in 100% Me2SO to a concentration of 25 mm and then diluted in 100% ethanol to a final concentration of 2.5 mm as a stock solution. It was added to protein-NADP complex solution (∼2 μl of this stock solution into 2 ml of total mixture volume) to reach a final concentration of 2.5 μm. The mixture was then concentrated 10-20 times before being diluted to ∼2 ml by adding the same stock buffer mentioned above. Additional EM1404 was added once more, which could be then dissolved (see “Discussion”). The same concentration-dilution procedure was repeated to saturate the enzyme substrate binding site by the inhibitor. The protein was finally concentrated to ∼10-15 mg/ml. The co-crystallization condition of the EM1404 ternary complex has been refined from the former conditions crystallizing testosterone and 4-dione complexes (36Zhou M. Qiu W. Chang H.J. Gangloff A. Lin S.X. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002; 58: 1048-1050Crossref PubMed Scopus (7) Google Scholar). The reservoir solution contained 100 mm sodium citrate, pH 5.6, 0.24 m ammonium acetate, and 30% PEG 4000. Human 17β-HSD5·NADP crystals were obtained at room temperature using the hanging-drop vapor diffusion method by mixing equal volumes of protein and a reservoir solution of 30% PEG 4000, 0.1 m sodium citrate, pH 5.6, 0.24 m ammonium acetate. During our first attempts, 17β-HSD5·NADP (final enzyme concentration 330 μm in the crystallization drop after equilibrium) binary complex crystals were soaked with repeated additions of EM1404 (final inhibitor concentration 560 μm), and similar crystal space groups were obtained (Table 1)TABLE 1Data collection and refinement statistics of crystal structures of 17β-HSD5·EM1404·NADP and 17β-HSD5·PEG·NADP17β-HSD5·EM1404·NADP17β-HSD5·PEG·NADPData processing statisticsPDB code1ZQ52FGBSpace groupP212121P212121Unit cell (Aå)a = 55.35, b = 62.78, c = 95.97a = 55.52, b = 61.65, c = 95.12Resolution range (Aå)29.8-1.3047.6-1.35Highest shell range (Aå)1.37-1.301.38-1.35Total reflections251,431 (23,897)aStatistics of the highest resolution shell are shown in parentheses.220,439 (7,354)aStatistics of the highest resolution shell are shown in parentheses.Unique reflections79,292 (10,401)68,648 (3,474)Mosaicity (°)0.320.38Multiplicity3.2 (2.3)3.2 (2.1)Completeness (%)95.9 (87.0)94.4 (65.2)Rmerge (%)bRmerge = ∑hkl∑j|Ij(hkl) - [I(hkl) ]|∑hkl∑j|Ij(hkl)|, where Ij(hkl) and [I(hkl) ] are the intensity of measurement j and the mean intensity for the reflection with indices hkl, respectively.5.4 (42.4)6.5 (47.5)Mean(I)/σ(I)11.9 (2.1)9.6 (2.0)Refinement statisticsReflections75,29368,644Resolution range (Aå)29.8-1.3047.6-1.35Highest shell range (Aå)1.33-1.301.38-1.35Rcryst (%)cRcryst and Rfree = ∑hkl||Fcalc(hkl)| - |Fobs(hkl)||/∑hkl|Fobs|, where the crystallographic and free R-factors are calculated, including and excluding refined reflections, respectively. The Rfree reflections set constituted 5% of the total number of reflections.18.1 (30.0)17.2 (25.9)Rfree (%)19.7 (35.4)19.0 (29.7)Average B-value (A2)Protein11.5115.5Ligand8.4412.5Water24.7726.9Root mean square deviation from idealityBonds (Aå)0.0080.007Angle (°)1.3321.255Ramachandran plot (% residue in CORE)91.893.2Model content321 residues, 315 H2O, 1 EM1404, 1NADP, and 1 acetate323 residues, 402 H2O, 1 PEG, 1 NADP, and 1 acetatea Statistics of the highest resolution shell are shown in parentheses.b Rmerge = ∑hkl∑j|Ij(hkl) - [I(hkl) ]|∑hkl∑j|Ij(hkl)|, where Ij(hkl) and [I(hkl) ] are the intensity of measurement j and the mean intensity for the reflection with indices hkl, respectively.c Rcryst and Rfree = ∑hkl||Fcalc(hkl)| - |Fobs(hkl)||/∑hkl|Fobs|, where the crystallographic and free R-factors are calculated, including and excluding refined reflections, respectively. The Rfree reflections set constituted 5% of the total number of reflections. Open table in a new tab Data Collection and Processing—Both datasets of 17β-HSD5·EM1404·NADP and 17β-HSD5·PEG fragment·NADP were collected at the X-8C beamline in National Synchrotron Light Source, Brookhaven National Laboratory. Datasets were processed using the Mosflm (39Leslie A.G.W. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography. 1992; (No. 26)Google Scholar) and HKL packages (40Otwinowski Z. Minor W. Methods Enzymol. 1997; 276: 307-326Crossref PubMed Scopus (38526) Google Scholar). The processing statistics data are given in Table 1. Structure Solution and Refinement—The initial phases of 17β-HSD5·EM1404·NADP was obtained from a molecular replacement method using the EPMR program (41Kissinger C.R. Gehlhaar D.K. Fogel D.B. Acta Crystallogr. Sect. D Biol. Crystallogr. 1999; 55: 484-491Crossref PubMed Scopus (690) Google Scholar). A data set from 15 to 4 Aå resolution was used in molecular replacement. The coordinates of the protein structure from the 17β-HSD5-testosterone-NADP complex in the P21 space group were used as the starting model. A correlation coefficient factor of 0.568 and an R-factor of 41.9% were obtained before any refinement. The initial phases of 17β-HSD5·PEG·NADP were obtained using a similar method. Starting from the molecular replacement model, the programs Resolve (42Terwilliger T.C. Acta Crystallogr. Sect. D Biol. Crystallogr. 2003; 59: 38-44Crossref PubMed Scopus (593) Google Scholar) and Refmac from the CCP4 package (43Number Collaborative Computational Project Acta Crystallogr. Sect. D Biol. Crystallogr. 1994; 50: 760-763Crossref PubMed Scopus (19748) Google Scholar) were used to improve phases using a statistical density modification method. Rigid body refinement was done with data from 29 to 3.0 Aå resolution. Automatic model rebuilding was carried out based on a prime-and-switch composite omit map to reduce any model bias due to refinement. Multiple refinement cycles were carried out using the program Refmac, and model building was done by the Coot program (44Emsley P. Cowtan K. Acta Crystallogr. Sect. D Biol. Crystallogr. 2004; 60: 2126-2132Crossref PubMed Scopus (23224) Google Scholar) based on sigma-A weighted 2Fo - Fc electron density maps. The last refinement steps were done with data from 29 to 1.30 Aå resolution. The inhibitor position was very clear in the substrate binding site from the electron density maps. An acetate molecule was also identified near the substrate and cofactor binding sites and was induced during the co-crystallization (see above). The program Coot was also used to add water into the model. In the final model, 356 water molecules were included with good hydrogen bonding geometry. Both structures have been deposited in the PDB, the ID for 17β-HSD5·EM1404·NADP structure is 1ZQ5, while that for 17β-HSD5·PEG fragment·NADP is 2FGB. Inhibition Study—A radioactive assay was used for the enzyme kinetics in the presence of EM1404 at different concentrations for its Ki determination. Purified 17β-HSD5, freshly frozen at -80 °C in small aliquots until use, has demonstrated very good reproduction of steady-state kinetics. The reactions were carried out in the presence of an excess of NADP (200 μm) at pH 7.5 and 37 ± 0.5 °C. The Km for testosterone oxidation in the absence of EM-1404, and four apparent Km values in the presence of 1, 3, 10, and 25 nm EM-1404, were determined. Reactions were initiated by the addition of enzyme sample to a final concentration of 200 nm in the reaction mixture, aliquots of the reaction mixture were taken, and the reaction was stopped at different time intervals by extracting the steroids with 2.5× vol. of diethyl ether. The steroids were extracted, separated by TLC migration in 80% toluene and 20% acetone for a 10-cm distance, and analyzed by phosphorimaging. Initial velocities were measured with <5% substrate consumption. The experiments were repeated with different concentrations of testosterone ranging from 0.8 to 10 μm. To obtain an optimal signal, larger reaction mixture volumes were used for low substrate concentrations (i.e. 3-ml reaction mixtures for 0.8 μm testosterone, 2 ml for 1.8 μm, 1 ml for 4 μm, and 0.5 ml for 10 μm). All experiments were performed in duplicate. IC50 values indicated the inhibitor concentration leading to 50% inhibition of the enzyme activity under the experimental conditions described in Ref. 34Labrie F. Belanger A. Gauthier S. Luu-The V. Merand Y. Poirier D. Provencher L. Singh S.M. Inhibitors of Type 5 and Type 3 17beta-Hydroxysteroid Dehydrogenase and Methods for Their Use. 1999; (Canada PCT, WO99/46279)Google Scholar. The values were calculate using Equation 1, 1/v=Km/Vmax⋅(1+[f]JK1)⋅1/[S]+1/VmaxEq. 1 where v is the initial velocity in the presence of different substrate concentrations, Vmax is the maximum velocity, and [S] and [I] are the substrate and inhibitor concentrations (48Segel L.A. J. Theor. Biol. 1976; 57: 23-42Crossref PubMed Scopus (26) Google Scholar). The respective apparent Km values in the presence of different inhibitor concentrations were then plotted versus these concentrations as shown by the inset of Fig. 5, the slope of which defines Km/Ki (48Segel L.A. J. Theor. Biol. 1976; 57: 23-42Crossref PubMed Scopus (26) Google Scholar), based on the linear regression of Equation 2. Kmapp=Km(1+[f]/Ki)Eq. 2 Molecular Dynamics Simulation—The simulations were based on the crystal structure for the complex EM1404 and the docked structure for the complex with the newly proposed inhibitor (Fig. 8C). MD simulations were performed with the program GROMACS (www.gromacs.org) version 3.3.1 (details are in the supplemental material). The GROMACS forcefield parameters were employed for the simulations. Overall Structure—The inhibitor EM1404 (3-carboxamido-1,3,5-(10Lin H.K. Jez J.M. Schlegel B.P. Peehl D.M. Pachter J.A. Penning T.M. Mol. Endocrinol. 1997; 11: 1971-1984Crossref PubMed Google Scholar)-estratrien-17(R)-spiro-2′-(5′, 5′-dimethyl-6′-oxo)tetrahydropyran, C25H30O3N, Fig. 1A) was first obtained from a chemical screen (34Labrie F. Belanger A. Gauthier S. Luu-The V. Merand Y. Poirier D. Provencher L. Singh S.M. Inhibitors of Type 5 and Type 3 17beta-Hydroxysteroid Dehydrogenase and Methods for Their Use. 1999; (Canada PCT, WO99/46279)Google Scholar) where it was shown to have an IC50 (see definition in method) of 3.2 ± 1.5 nm, the best among the inhibitors designed for 17β-HSD5. The strong affinity of EM1404 is further proven in the inhibition mechanism study below. The ternary complex structure of 17β-HSD5·EM1404·NADP was determined by molecular replacement using a searching model obtained from the 17β-HSD5·testosterone·NADP complex (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar). Its overall structure is similar to the other crystal forms (19Qiu W. Zhou M. Labrie F. Lin S-X. Mol. Endocrinol. 2004; 18: 1798-1807Crossref PubMed Scopus (65) Google Scholar, 20Komoto J. Yamada T. Watanabe K. Takusagawa F. Biochemistry. 2004; 43: 2188-2198Crossref PubMed Scopus (84) Google Scholar, 21Lovering A.L. Ride J.P. Bunce C.M. Desmond J.C. Cummings S.M. White S.A. Cancer Res. 2004; 64: 1802-1810Crossref PubMed Scopus (103) Google Scholar), with an (α/β)8 triose-phosphate isomerase barrel motif, a typical structure of the aldoketo reductase family. Four large loops, namely loop-A (24Rheault P. Dufort I. Soucy P. Luu-The V. Cytogenet. Cell Genet. 1999; 84: 241-242Crossref PubMed Google Scholar, 25Koh E. Noda T. Kanaya J. Namiki M. Prostate. 2002; 53: 154-159Crossref PubMed Scopus (82) Google Scholar, 26Bartsch W. Greeve J. Voigt K.D. J. Steroid. Biochem. 1987; 28: 35-42Crossref PubMed Scopus (17) Google Scholar, 27Martel C. Rheaume E. Takahashi M. Trudel C. Couet J. Luu-The V. Simard J. Labrie F. J. Steroid Biochem. Mol. Biol. 1992; 41: 597-603Crossref PubMed Scopus (234) Google Scholar, 28Soronen P. Laiti M. Torn S. Harkonen P. Patrikainen L. Li Y. Pulkka A. Kurkela R. Herrala A. Kaija H. Isomaa V. Vihko P. J. Steroid Biochem. Mol. Biol. 2004; 92: 281-286Crossref PubMed Scopus (70) Google Scholar, 29Oduwole O.O. Li Y. Isomaa V.V. Manty